| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Cecilia Riquelme, María José Acuña, Javiera Torrejón, Daniela Rebolledo, Daniel Cabrera, Robson A Santos, Enrique Branda. ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis. PloS one. vol 9. issue 4. 2015-01-20. PMID:24695436. |
duchenne muscular dystrophy (dmd) is the most common inherited neuromuscular disease and is characterized by absence of the cytoskeletal protein dystrophin, muscle wasting, and fibrosis. |
2015-01-20 |
2023-08-13 |
mouse |
| María José Acuña, Patrizia Pessina, Hugo Olguin, Daniel Cabrera, Carlos P Vio, Michael Bader, Pura Muñoz-Canoves, Robson A Santos, Claudio Cabello-Verrugio, Enrique Branda. Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling. Human molecular genetics. vol 23. issue 5. 2014-10-15. PMID:24163134. |
duchenne muscular dystrophy (dmd) is the most common inherited neuromuscular disease, and is characterized by the lack of dystrophin, muscle wasting, increased transforming growth factor (tgf)-β smad-dependent signalling and fibrosis. |
2014-10-15 |
2023-08-12 |
mouse |
| Elisabeth Sarrazin, Maja von der Hagen, Ulrike Schara, Katja von Au, Angela M Kaind. Growth and psychomotor development of patients with Duchenne muscular dystrophy. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 18. issue 1. 2014-10-12. PMID:24100172. |
duchenne muscular dystrophy (dmd) is one of the most common hereditary degenerative neuromuscular diseases and caused by mutations in the dystrophin gene. |
2014-10-12 |
2023-08-12 |
Not clear |
| Amparo Gutierrez, John D Englan. Administration of glucocorticoids in boys with Duchenne muscular dystrophy. Continuum (Minneapolis, Minn.). vol 19. issue 6 Muscle Disease. 2014-08-11. PMID:24305455. |
duchenne muscular dystrophy (dmd) is the most common neuromuscular disease affecting boys. |
2014-08-11 |
2023-08-12 |
Not clear |
| D Wang, Z J Wang, X X Song, L H Pu, X Li, Y Wan. Analysis of differentially expressed genes in various stages of Duchenne muscular dystrophy by using a network view. Genetics and molecular research : GMR. vol 12. issue 4. 2014-06-30. PMID:24222227. |
duchenne muscular dystrophy (dmd), which is caused by mutations in the x-linked dystrophin gene, is a severe and progressive neuromuscular disease with no available cure. |
2014-06-30 |
2023-08-12 |
Not clear |
| Andrew G L Douglas, Matthew J A Woo. Splicing therapy for neuromuscular disease. Molecular and cellular neurosciences. vol 56. 2014-06-20. PMID:23631896. |
duchenne muscular dystrophy (dmd) and spinal muscular atrophy (sma) are two of the most common inherited neuromuscular diseases in humans. |
2014-06-20 |
2023-08-12 |
Not clear |
| Jean Giacomotto, Nicolas Brouilly, Ludivine Walter, Marie-Christine Mariol, Joachim Berger, Laurent Ségalat, Thomas S Becker, Peter D Currie, Kathrin Giesele. Chemical genetics unveils a key role of mitochondrial dynamics, cytochrome c release and IP3R activity in muscular dystrophy. Human molecular genetics. vol 22. issue 22. 2014-06-03. PMID:23804750. |
duchenne muscular dystrophy (dmd) is a neuromuscular disease caused by mutations in the dystrophin gene. |
2014-06-03 |
2023-08-12 |
caenorhabditis_elegans |
| Ryan D Wuebbles, Apurva Sarathy, Joe N Kornegay, Dean J Burki. Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy. Disease models & mechanisms. vol 6. issue 5. 2014-04-22. PMID:23846963. |
duchenne muscular dystrophy (dmd) is a fatal neuromuscular disease for which there is no cure and limited treatment options. |
2014-04-22 |
2023-08-12 |
mouse |
| Kristy Swiderski, Michelle Todorov, Stefan M Gehrig, Timur Naim, Annabel Chee, David I Stapleton, René Koopman, Gordon S Lync. Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice. Fibrogenesis & tissue repair. vol 7. issue 1. 2014-02-03. PMID:24476069. |
novel treatments that can prevent or attenuate fibrosis have important clinical merit for dmd and related neuromuscular diseases. |
2014-02-03 |
2023-08-12 |
mouse |
| Mohammed T Taye. Deletion mutations in Duchenne muscular dystrophy (DMD) in Western Saudi children. Saudi journal of biological sciences. vol 17. issue 3. 2013-08-20. PMID:23961084. |
the disease is an x-linked neuromuscular diseases typically caused by disrupting (dmd) or non-disrupting (bmd) the reading frame in the dystrophin (dmd) gene. |
2013-08-20 |
2023-08-12 |
Not clear |
| Ruth McGowan, Benjamin R Challoner, Sarah Ross, Susan Holloway, Shelagh Joss, Douglas Wilcox, Simon T Holden, John Tolmie, Cheryl Longma. Results of Duchenne muscular dystrophy family screening in practice: leaks rather than cascades? Clinical genetics. vol 83. issue 2. 2013-08-05. PMID:22428906. |
duchenne muscular dystrophy (dmd) is a progressive neuromuscular disease caused by mutations in the gene that encodes the protein dystrophin. |
2013-08-05 |
2023-08-12 |
Not clear |
| Gregory T Carter, Nanette C Joyce, Allison L Abresch, Amanda E Smith, Gregg K VandeKeif. Using palliative care in progressive neuromuscular disease to maximize quality of life. Physical medicine and rehabilitation clinics of North America. vol 23. issue 4. 2013-05-22. PMID:23137745. |
this article discusses the role of palliative care in the treatment pathway of patients with progressive neuromuscular disease (ndm), including amyotrophic lateral sclerosis and duchenne muscular dystrophy (dmd). |
2013-05-22 |
2023-08-12 |
Not clear |
| Sarah K Gray, Meghan E McGee-Lawrence, Jennifer L Sanders, Keith W Condon, Chung-Jui Tsai, Seth W Donahu. Black bear parathyroid hormone has greater anabolic effects on trabecular bone in dystrophin-deficient mice than in wild type mice. Bone. vol 51. issue 3. 2012-12-17. PMID:22584007. |
duchenne muscular dystrophy (dmd) is an x-linked neuromuscular disease that has deleterious consequences in muscle and bone, leading to decreased mobility, progressive osteoporosis, and premature death. |
2012-12-17 |
2023-08-12 |
mouse |
| R Renjini, N Gayathri, A Nalini, M M Srinivas Bharat. Oxidative damage in muscular dystrophy correlates with the severity of the pathology: role of glutathione metabolism. Neurochemical research. vol 37. issue 4. 2012-11-26. PMID:22219131. |
muscular dystrophies (mds) such as duchenne muscular dystrophy (dmd), sarcoglycanopathy (sgpy) and dysferlinopathy (dysfy) are recessive genetic neuromuscular diseases that display muscle degeneration. |
2012-11-26 |
2023-08-12 |
mouse |
| Nevenka Juretić, Gonzalo Jorquera, Pablo Caviedes, Enrique Jaimovich, Nora Rivero. Electrical stimulation induces calcium-dependent up-regulation of neuregulin-1β in dystrophic skeletal muscle cell lines. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. vol 29. issue 5-6. 2012-11-08. PMID:22613991. |
duchenne muscular dystrophy (dmd) is a neuromuscular disease originated by reduced or no expression of dystrophin, a cytoskeletal protein that provides structural integrity to muscle fibres. |
2012-11-08 |
2023-08-12 |
human |
| Justin M Percival, Nicholas P Whitehead, Marvin E Adams, Candace M Adamo, Joseph A Beavo, Stanley C Froehne. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. The Journal of pathology. vol 228. issue 1. 2012-10-09. PMID:22653783. |
pde5 inhibitors serve to amplify no signalling that is attenuated in many neuromuscular diseases including dmd. |
2012-10-09 |
2023-08-12 |
mouse |
| Shin'ichi Taked. [Exon-skipping therapy for Duchenne muscular dystrophy]. Rinsho shinkeigaku = Clinical neurology. vol 51. issue 11. 2012-09-18. PMID:22277414. |
clinical trials of exon 51 skipping for dmd patients is now going in our country and application of antisense strategy to other hereditary neuromuscular diseases is largely expected. |
2012-09-18 |
2023-08-12 |
mouse |
| Roxanna M Bendixen, Claudia Senesac, Donovan J Lott, Krista Vandenborn. Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health. Health and quality of life outcomes. vol 10. 2012-07-18. PMID:22545870. |
dmd is one of the most devastating genetically linked neuromuscular diseases for which there is currently no cure. |
2012-07-18 |
2023-08-12 |
Not clear |
| Nabeel Ahmad, Ian Welch, Robert Grange, Jennifer Hadway, Savita Dhanvantari, David Hill, Ting-Yim Lee, Lisa M Hoffma. Use of imaging biomarkers to assess perfusion and glucose metabolism in the skeletal muscle of dystrophic mice. BMC musculoskeletal disorders. vol 12. 2012-04-19. PMID:21639930. |
duchenne muscular dystrophy (dmd) is a severe neuromuscular disease that affects 1 in 3500 boys. |
2012-04-19 |
2023-08-12 |
mouse |
| John B Bodensteiner, Yu-Tze N. Ethical considerations in paediatric neurology: neuromuscular disease and epilepsy. Journal of paediatrics and child health. vol 47. issue 9. 2012-02-01. PMID:21951440. |
for neuromuscular disease, the example of duchenne muscular dystrophy (dmd) with regards to genetic testing, relatively early wheelchair placement and individualised invasive ventilation is discussed. |
2012-02-01 |
2023-08-12 |
human |